6ZB Stock Overview
A private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Linc AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 6.33 |
| 52 Week High | SEK 8.66 |
| 52 Week Low | SEK 4.55 |
| Beta | 1.03 |
| 11 Month Change | -10.85% |
| 3 Month Change | -16.82% |
| 1 Year Change | 37.16% |
| 33 Year Change | -24.89% |
| 5 Year Change | n/a |
| Change since IPO | -39.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6ZB | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | -4.4% | 0.5% | -1.3% |
| 1Y | 37.2% | 26.7% | 7.4% |
Return vs Industry: 6ZB exceeded the German Capital Markets industry which returned 26.7% over the past year.
Return vs Market: 6ZB exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 6ZB volatility | |
|---|---|
| 6ZB Average Weekly Movement | 4.7% |
| Capital Markets Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6ZB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6ZB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2 | Karl Tobieson | linc.se |
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies.
Linc AB Fundamentals Summary
| 6ZB fundamental statistics | |
|---|---|
| Market cap | €388.26m |
| Earnings (TTM) | €137.49m |
| Revenue (TTM) | €136.56m |
2.8x
P/E Ratio2.8x
P/S RatioIs 6ZB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6ZB income statement (TTM) | |
|---|---|
| Revenue | SEK 1.57b |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 1.57b |
| Other Expenses | -SEK 10.64m |
| Earnings | SEK 1.58b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 27.30 |
| Gross Margin | 100.00% |
| Net Profit Margin | 100.68% |
| Debt/Equity Ratio | 0% |
How did 6ZB perform over the long term?
See historical performance and comparison